The sources behind what we say
about autoimmune disease and menopause.

Approximately 78% of people with autoimmune disease are women, a sex bias that holds across lupus, Sjögren's, Hashimoto's, RA and MS.

The most-cited figure for the female:male skew in autoimmunity, and the one most patient-facing resources use as their starting point.

Estrogen is broadly immune-modulating: low and high physiological levels shift T-helper balance and B-cell activity in opposite directions, which helps explain why some autoimmune conditions flare in pregnancy and others remit, and why menopause can change the picture again.

Klein & Flanagan · sex differences in immunity

The standard reference for 'why women's immune systems behave differently from men's, and why that changes across the reproductive lifespan'.

Incomplete X-chromosome inactivation in immune cells gives genetically female individuals a higher 'dose' of several immune genes, and is now considered a plausible contributor to the autoimmune sex bias.

Dou et al · Xist ribonucleoprotein and autoimmunity

More recent mechanism work, useful background if you want to know why 'it's just hormones' isn't the whole story.

Hashimoto's thyroiditis and other thyroid autoimmunity peak in incidence in women between 45 and 55, the same window as perimenopause; symptom overlap (fatigue, weight change, low mood, cognitive change) is near-total.

Vanderpump · epidemiology of thyroid disease

If your perimenopause picture includes fatigue + cold + hair changes + low mood, asking for TSH plus thyroid antibodies (anti-TPO, anti-Tg) is reasonable, not over-investigating.

Sjögren's syndrome (dry eyes, dry mouth, fatigue, joint pain) has its peak diagnostic age in the early 50s, with most patients reporting symptoms for years before diagnosis.

Qin et al · Sjögren's epidemiology meta-analysis

Dry eyes and dry mouth in midlife are usually attributed to GSM-adjacent mucosal changes or just 'getting older'. Sjögren's is the named differential, particularly when fatigue and joint pain are also in the picture.

Rheumatoid arthritis incidence rises in women after the final menstrual period, and early postmenopause is associated with worse disease activity in existing RA.

Counter to the 'estrogen withdrawal is protective for autoimmunity' assumption. For RA specifically, the menopause transition is a worse-disease signal, not a better one.

Polymyalgia rheumatica (sudden bilateral shoulder/hip girdle stiffness, raised inflammatory markers, dramatic steroid response) almost exclusively presents after age 50 and is more common in women.

Useful to know about because the morning stiffness can read as 'menopausal joint pain' until ESR/CRP get checked. PMR responds spectacularly to low-dose prednisolone, which is also the diagnostic clue.

ANA (antinuclear antibody) is the standard initial screen for connective-tissue autoimmune disease; a positive ANA in the right clinical context triggers more specific antibody testing.

ANA is sensitive, not specific. Many healthy women have low-titre positive ANA. The test earns its keep when symptoms are systemic, not as a routine 'just in case'.

TSH plus anti-TPO antibodies is the recommended first-line workup for suspected autoimmune thyroid disease and is appropriate when fatigue, weight change, hair change or low mood are prominent.

TSH alone misses early autoimmune thyroiditis. If you've had a 'normal TSH' and the picture still fits, asking for anti-TPO is reasonable.

Anti-CCP antibodies and rheumatoid factor (RF) together are the standard serological workup for suspected rheumatoid arthritis; anti-CCP can be positive years before clinical disease.

If joint pain is symmetric, lasts more than 30 minutes of morning stiffness, and involves the small joints of the hands or feet, this is the panel to ask for, plus ESR and CRP.

ESR and CRP are non-specific inflammatory markers that, when persistently raised alongside symptoms, support escalation to a rheumatology referral.

Cheap, routine, often skipped in 'menopause' workups. Worth including when the symptom picture is systemic, not localised.

Up to 4–30% of POI cases (estimates vary by population and assay) have an autoimmune basis, most commonly with co-existing autoimmune thyroid or adrenal disease.

ESHRE's POI guideline is the modern international reference. The autoimmune workup (adrenal antibodies, thyroid antibodies) is part of the recommended evaluation, not an optional extra.

Women with POI have a markedly higher lifetime risk of co-existing autoimmune disease than age-matched controls, including Addison's disease, type 1 diabetes, and Hashimoto's.

Useful citation when asking a GP or endocrinologist for an autoimmune screen at POI diagnosis. The clustering is the point, one autoimmune diagnosis raises the prior probability of another.